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Abstract
Background:  Pain  due  to  injection  propofol  is  a  common  problem.  Different  methods  are  used  to
decrease the  pain  but  with  limited  success.  The  objective  of  this  study  was  to  assess  the  effect
of injection  dexmedetomidine  0.2  mcg/kg  for  prevention  of  pain  due  to  propofol  injection  and
compare it  with  injection  lignocaine  0.2  mg/kg.
Method:  After  taking  permission  of  the  Institutional  Ethical  Committee,  written  informed  con-
sent was  obtained  from  all  patients,  in  a  randomized  prospective  study.  60  American  Society
of Anesthesiology  I  and  II  patients  of  age  range  20--60  years  of  either  sex  posted  for  elec-
tive surgeries  under  general  anaesthesia  were  randomly  allocated  into  two  groups.  Group  I
(dexmedetomidine  group):  Inj.  dexmedetomidine  0.2  mcg/kg  diluted  in  5  mL  normal  saline  and
Group II  (lignocaine  group):  Inj.  lignocaine  0.2  mg/kg  diluted  in  5  mL  normal  saline.  IV  line
was secured  with  20  G  cannula  and  venous  occlusion  was  applied  to  forearm  using  a  pneu-
matic tourniquet  and  inﬂated  to  70  mm  Hg  for  1  min.  Study  drug  was  injected,  tourniquet
released and  then  25%  of  the  calculated  dose  of  propofol  was  given  intravenously  over  10  s.
After 10  s  of  injection,  severity  of  pain  was  evaluated  using  McCrirrick  and  Hunter  scale  and
then remaining  propofol  and  neuromuscular  blocking  agent  was  given.  Endotracheal  intubation
was done  and  anaesthesia  was  maintained  on  O2,  N2O  and  isoﬂurane  on  intermittent  positive
pressure ventilation  with  Bain’s  circuit  and  inj.  vecuronium  was  used  as  muscle  relaxant.
Results: Demographic  data  showed  that  there  was  no  statistically  signiﬁcant  difference
between  the  2  groups.  There  was  no  statistically  signiﬁcant  difference  between  2  groups  in
respect to  inj.  propofol  pain.  No  adverse  effects  like  oedema,  pain,  wheal  response  at  the  site
of injection  were  observed  in  the  two  groups.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Published  by  Elsevier  Editora  Ltda.  All  rights
reserved.∗ Corresponding author.
E-mail: manisha.sapate@gmail.com (M. Sapate).
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Avaliac¸ão  do  efeito  de  dexmedetomidina  na  prevenc¸ão  da  dor  relacionada  à  injec¸ão
de  propofol  e  comparac¸ão  com  o  efeito  da  injec¸ão de  lidocaína
Resumo
Justiﬁcativa  e  objetivo:  A  dor  relacionada  à  injec¸ão  de  propofol  é  um  problema  comum.  Méto-
dos diferentes  são  usados  para  diminuí-la,  mas  com  sucesso  limitado.  O  objetivo  deste  estudo  foi
avaliar o  efeito  da  dexmedetomidina  (0,2  mcg  kg−1)  na  prevenc¸ão  da  dor  relacionada  à  injec¸ão
de propofol  e  compará-lo  com  lidocaína  (0,2  mg  kg−1).
Método:  Depois  da  permissão  do  Comitê  de  Ética  Institucional,  a  assinatura  do  termo  de  consen-
timento  informado  foi  obtida  de  todos  os  participantes  deste  estudo  prospectivo  e  randomizado.
Sessenta pacientes  com  estado  físico  ASA  I-II,  idades  entre  20-60  anos,  de  ambos  os  sexos  e
programados  para  cirurgias  eletivas  sob  anestesia  geral  foram  randomicamente  alocados  em
dois grupos:  Grupo  I  (dexmedetomidina)  recebeu  injec¸ão  de  dexmedetomidina  (0,2  mcg  kg−1)
diluída em  5  mL  de  soluc¸ão  salina  normal  e  Grupo  II  (lidocaína)  recebeu  injec¸ão  de  lidocaína
(0,2 mg  kg−1)  diluída  em  5  mL  de  soluc¸ão  salina  normal.  O  acesso  IV  foi  obtido  com  uma  cânula  de
calibre 20G  e  a  oclusão  venosa  aplicada  no  antebrac¸o com  o  uso  de  um  torniquete  pneumático
e inﬂado  a  70  mm  Hg  durante  um  minuto.  Os  medicamentos  em  estudo  foram  injetados,  o  torni-
quete foi  liberado  e,  em  seguida,  25%  da  dose  calculada  de  propofol  foi  administrada  por  via
intravenosa durante  10  segundos.  Após  10  segundos  de  injec¸ão,  a  intensidade  da  dor  foi  avali-
ada com  o  uso  da  escala  de  McCrirrick  e  Hunter  e,  em  seguida,  o  restante  do  propofol  e  um
agente bloqueador  neuromuscular  foram  administrados.  A  intubac¸ão  endotraqueal  foi  feita  e  a
anestesia mantida  com  O2,  N2O  e  isoﬂurano  em  ventilac¸ão  com  pressão  positiva  intermitente,
com o  circuito  de  Bain  e  uso  de  vecurônio  como  relaxante  muscular.
Resultados:  Os  dados  demográﬁcos  mostraram  que  não  houve  diferenc¸a  estatisticamente  sig-
niﬁcante entre  os  dois  grupos.  Não  houve  diferenc¸a  estatisticamente  signiﬁcante  entre  os  dois
grupos em  relac¸ão  à  dor  relacionada  à  injec¸ão  de  propofol.  Não  houve  efeitos  adversos,  como
edema, dor  e  pápula  no  local  da  injec¸ão  nos  dois  grupos.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
direitos reservados.
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Pain  is  an  unpleasant  subjective  sensation  which  is  very  dis-
tressing  to  the  patient.  Pain  on  injection  with  propofol  is
a  common  problem.1,2 It  is  due  to  phenol  group  present
in  propofol.  Phenol  group  is  irritating  to  skin,  mucous
membrane  and  venous  intima.  In  the  absence  of  treat-
ment  regimens,  28--90%  of  patients  experience  moderate  to
severe  pain  when  propofol  is  injected  into  peripheral  vein.1
Various  methods  have  been  used  to  decrease  the  severity  of
pain  like  Nitroglycerine  ointment  at  the  injection  site,  dilut-
ing  propofol  with  5%  dextrose  or  intralipid,  inj.  ondensetron
or  opioids  such  as  fentanyl,  NSAIDs.  Intravenous  Lignocaine
is  the  most  commonly  used  pre-treatment  to  reduce  the  pain
caused  by  inj.  propofol.  It  is  deﬁnitely  effective  but  it  also
has  a  failure  rate  of  13--32%.3,4
Dexmedetomidine  is  a  highly  selective,  speciﬁc  and
potent  alpha-2  adrenoreceptor  agonist.  It  is  a  potent  anal-
gesic,  sedative,  along  with  sympatholytic  effect.  In  addition,
it  has  supraspinal,  spinal  and  peripheral  action.  Alpha
2-adrenoreceptors  located  on  blood  vessels  inhibit  nor-
epinephrine  release,  resulting  in  release  of  prostaglandins
and  cause  vasodilation  that  antagonize  the  venoconstrictor
response.5 Dexmedetomidine  has  been  shown  to  promote
6peripheral  antinociception. Therefore  dexmedetomidine
can  also  be  used  for  relief  of  propofol  pain.  Lignocaine
is  a  time  tested  local  anaesthetic  belonging  to  the  ester
group.
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wIn  the  present  study,  we  plan  to  investigate  the  effect  of
nj.  dexmedetomidine  for  prevention  of  propofol  injection
ain  and  compare  it  with  inj.  Lignocaine.
ethods
he  study  was  conducted  after  obtaining  the  approval  from
nstitutional  ethical  committee.  A  written  and  informed
onsent  was  obtained  from  all  patients.  60  patients  were
ncluded  in  our  study.  All  these  patients  belonged  to  Amer-
can  Society  of  Anesthesiology  (ASA)  grade  I  or  II and  were
osted  for  elective  surgery  under  General  Anaesthesia.
horough  preoperative  evaluation  was  done.  Patients  were
ept  fasting  for  6  h.  Randomization  was  done  into  2  groups
y  double  blind  method.  Group  I  (dexmedetomidine  group)
n  which  inj.  dexmedetomidine  0.2  mcg/kg  diluted  in  5  mL
ormal  saline  and  Group  II  (lignocaine  group)  in  which  inj.
ignocaine  0.2  mg/kg  diluted  in  5  mL  normal  saline  were
iven.
Exclusion  criteria  for  this  study  were  patients  unwilling
or  the  trial,  those  requiring  rapid  sequence  induction  and
hose  with  anticipated  difﬁculty  in  venous  access.
On  arrival  of  patient  to  the  operation  theatre,  a  20  G
ntravenous  cannula  was  inserted  in  a  prominent  vein  on
orsum  of  non-dominant  hand.  All  monitors  like  electro-
ardiogram,  non-invasive  blood  pressure  and  pulse  oximeter
ere  attached.  A  pneumatic  tourniquet  was  placed  on  the
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Table  1  McCrirrick  and  Hunter  Scale  for  evaluation  of  pain.
Degree  of  pain  Response
None  (0)  No  response  to  questioning
Mild (1)  Pain  reported  in  response  to
questioning  only  without  any
behavioural  signs
Moderate  (2)  Pain  reported  in  response  to
questioning  and  accompanied
by  behavioural  signs  or  pain
reported  spontaneously
without  questioning
Severe  (3)  Strong  vocal  response  or
response  accompanied  by
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Figure  1  Demographic  data.  Table  2  shows  overall  incidence
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ame  upper  arm  with  pressure  inﬂated  to  70  mm  Hg  to  pro-
uce  venous  occlusion.
The  study  drugs  were  preservative  free  and  kept  at
oom  temperature.  Each  of  the  study  drug  was  prepared
y  independent  Anaesthesiologists  into  5  mL  volume.  The
ourniquet  was  inﬂated  for  1  min  and  study  drug  were  given
ntravenously  over  5  s  and  then  tourniquet  was  released.  25%
f  the  calculated  dose  of  propofol  was  given  intravenously
ver  10  s.  After  10  s  severity  of  pain  was  evaluated  using
cCrirrick  and  Hunter  Scale2 (Table  1)  which  was  already
xplained  to  the  patient.  Then  remaining  propofol  and
euromuscular  blocking  agent  (inj.  vecuronium  0.08  mg/kg)
ere  given  &  endotracheal  intubation  were  done  with  appro-
riate  size  tube.  Anaesthesia  was  maintained  with  O2,  N2O
nd  Isoﬂurane  on  intermittent  positive  pressure  with  Bain’s
ircuit  and  Inj  Vecuronium  was  used  as  muscle  relaxant.
tatistical  analysisnalysis  was  performed  using  the  program  SPSS  (Statistical
ackage  For  Social  Services)  version  for  windows.  The  data
ere  reported  as  a  mean  ±  SD,  median  and  numbers  (%)  as
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Table  2  Demographic  data.  The  demographic  data  were  compar
Demographic  data  Group  I  (dexmedetomidine)  
Age  (yr)  45.4  ±  16.11  
Male/female  16/14  
Weight 57.92  ±  8.41  
There was no signiﬁcant statistical difference among the 2 groups in re
clinically insigniﬁcant (Fig. 1).
a p value -- probability/test of signiﬁcance.
Table  3  Severity  of  pain  score.
Pain  score  Group  I  (dexmedetomidine)  
None  (0)  15  (50%)  
Mild (1)  9  (30%)  
Moderate (2)  6  (20%)  
Severe (3)  0  
a p value < 0.005 i.e. not signiﬁcant.nd severity  of  pain  after  injection  of  propofol  in  the  two
roups.
ound  suitable.  Relationships  between  categorical  variables
ere  tested  using  the  Chi  Square  Test.  Two  sample  t-test
as  used  for  comparison  of  normally  distributed  continuous
ariables  between  the  two  groups.  p  Value  more  than  0.05
as  considered  as  statistically  signiﬁcant  (Fig.  1,  Table  2).
esults
ifteen  patients  (50%)  in  Group  I  and  eighteen  patients  (60%)
n  Group  II  had  no  pain  on  inj.  propofol.  Nine  patients  (30%)
n  dexmedetomidine  group  and  eight  patients  (27%)  in  ligno-
aine  group  had  mild  pain.  Six  patients  (20%)  in  Group  I  and
our  patients  (13%)  in  Group  II  had  moderate  pain  (Table  3,
ig.  2).  The  study  showed  that  there  was  no  difference  in  the
ain  score  which  was  statistically  signiﬁcant.  No  patient  in
his  study  had  severe  pain.  No  adverse  effects  like  oedema,
ain,  wheal  response  at  the  site  of  injection  were  observed
n  the  study.iscussion
ropofol  induced  pain  is  considered  to  be  one  of  the  most
mportant  problems  of  current  clinical  practice.  It  was  rated
ed  among  the  two  groups.
Group  II  (lignocaine)  p  valuea
40.72  ±  13.96  >0.05
15/15  <0.05
61.88  ±  5.91  <0.05
lation to the weight and sex except the age parameter which was
Group  II  (lignocaine)  p  valuea
18  (60%)  <0.005
8  (27%)  <0.005
4  (13%)  <0.005
0
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Figure  2  Severity  of  pain  score.
as  the  seventh  most  disturbing  experience  to  the  patient  in
anaesthesia  practice  by  a  group  of  experts.7 Nature  of  the
vascular  pain  is  expressed  by  the  patients  as  aching,  burn-
ing  and  crushing.  Inj.  propofol  has  a  phenol  group  which  is
irritating  to  skin,  mucous  membrane  and  venous  intima.8
Mechanism  of  immediate  pain  is  due  to  irritation  of  affer-
ent  nerve  endings  within  the  vein.  Scott  et  al.3 speculated
that  mechanism  of  the  delayed  pain  is  due  to  activation
of  kallikrien--kinin  system  by  propofol,  thereby  generating
kinin,  probably  bradykinin.  It  produces  local  vasodilation
and  hyperpermeability.  It  increases  contact  between  propo-
fol  and  free  nerve  endings  resulting  in  pain  on  injection.9
The  use  of  adjuvant  medication  before  propofol  to  reduce
the  pain  of  injection  has  become  a  common  practice.
The  0.2  mcg/kg  dexmedetomidine  dose  was  chosen
according  to  a  study  of  Memis  et  al.10 where  they  compared
0.1  mcg/kg  and  0.2  mcg/kg  dexmedetomidine  for  decreasing
rocuronium  injection  pain  and  they  concluded  that  the  latter
dose  was  more  effective.
Ayoglu  et  al.11 in  their  comparative  study  of  dexmedeto-
midine  with  lignocaine  for  their  effect  on  reducing  propofol
and  rocuronium  injection  pain  concluded  that  dexmedeto-
midine  failed  to  decrease  propofol  injection  pain  but
reduced  rocuronium  withdrawal  movement.
Comparison  of  0.2  mcg/kg  of  dexmedetomidine  with
placebo  for  propofol  pain  was  studied  by  Uzun  et  al.12 who
concluded  that  injection  of  dexmedetomidine  before  propo-
fol  was  found  to  be  more  effective  than  injection  of  normal
saline  in  alleviating  propofol  injection  pain.
Alpha  1-  and  alpha  2-stimulation  might  be  a  possi-
ble  mechanism  involved  in  decreasing  propofol  injection
pain  and  resulting  in  release  of  prostaglandins  which  cause
vasodilation  that  antagonize  venoconstrictor  response.  This
modulates  the  sympathetic  response  of  venous  smooth
muscle  and  may  be  important  in  endothelial  dysfunction
caused  by  propofol.13 This  might  be  the  basic  mechanism
of  action  with  dexmedetomidine  as  it  is  highly  potent
alpha2  adrenoreceptor  agonist.  Another  mechanism  might
1ine  469
e  hyper-polarisation  activated  conductance  in  peripherally
ediated  antinociception.
Mechanism  of  action  in  lignocaine  for  propofol  pain  relief
s  due  to  local  anaesthetic  effect  which  causes  an  inhibitory
ffect  on  the  enzymatic  cascade  leading  to  release  of  kinin.
onclusion
nj.  Dexmedetomidine  is  equally  effective  and  can  be  used  as
n  alternative  to  time  tested  drug  inj.  Lignocaine  for  relief
f  pain  due  to  propofol  injection  without  any  signiﬁcant  side
ffects.
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